Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Inventory (2021 - 2026)

ADC Therapeutics has reported Inventory over the past 6 years, most recently at $4.8 million for Q1 2026.

  • Quarterly results put Inventory at $4.8 million for Q1 2026, down 72.63% from a year ago — trailing twelve months through Mar 2026 was $4.8 million (down 72.63% YoY), and the annual figure for FY2025 was $4.2 million, up 85.87%.
  • Inventory reached $4.8 million in Q1 2026 per ADCT's latest filing, up from $4.2 million in the prior quarter.
  • Across five years, Inventory topped out at $22.7 million in Q3 2023 and bottomed at $11838.0 in Q1 2022.
  • Median Inventory over the past 5 years was $16.1 million (2022), compared with a mean of $13.8 million.
  • The largest annual shift saw Inventory soared 196515.88% in 2022 before it crashed 86.09% in 2024.
  • Over 5 years, Inventory stood at $16.1 million in 2022, then increased by 0.69% to $16.2 million in 2023, then tumbled by 86.09% to $2.3 million in 2024, then skyrocketed by 85.87% to $4.2 million in 2025, then rose by 14.15% to $4.8 million in 2026.
  • Business Quant data shows Inventory for ADCT at $4.8 million in Q1 2026, $4.2 million in Q4 2025, and $18.0 million in Q3 2025.